<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=319805651697215&amp;ev=PageView&amp;noscript=1">

Logistics Advancements and Trends in the Biopharma Industry

December 01, 2016

For successful commercial distribution, advanced cellular therapies require secure, well-designed cold chain management solutions based on effective packaging, informatics and logistics expertise. Advancements in the rigorous control of the commodity environment have focused in four areas: equipment, refrigerant, IT/data management and analysis, and processes and programmatic integration. In an article in World Pharma Today, Mark W. Sawicki, Ph.D., chief commercial officer of Cryoport, discusses how next-generation biopharmaceuticals can benefit from these developments as well as earlier engagement of supply chain planning in the clinical trial design process. Read more >


Cold Chain Challenges Evolving With Industry

November 23, 2016

To ensure the safety and efficacy of inherently fragile regenerative medicines and other temperature-sensitive clinical trial therapeutics and biospecimens, the materials must be maintained within a narrow range of temperatures during shipment and storage. In an interview with Outsourcing-Pharma.com, Mark W. Sawicki, Ph.D., chief commercial officer of Cryoport, discusses the growing complexities of cold chain logistics, including the need for advanced equipment and processes and adherence to international shipping regulations. Read more >


Cold Chain Planning for Regenerative Medicine Clinical Studies

November 01, 2016

The advent of regenerative therapy — a field that includes gene therapy, gene editing, stem cell therapy and immuno-oncology — is creating an unprecedented need for cold chain logistics. According to the Alliance for Regenerative Medicine, there are 70 approved cell therapies currently being marketed and at least 728 ongoing regenerative medicine clinical trials involving thousands of patients for a variety of clinical indications. Although manufacturers go to great lengths to ensure that their highly valuable products are produced under rigorous standards, they may fail to adequately consider these standards when planning the logistics of handling, packaging or transporting materials from one location to another. In this article, Mark W. Sawicki, Ph.D., Cryoport’s chief commercial officer, examines the need for comprehensive cold chain planning for clinical studies in regenerative medicines, and he details current best practices. Read more >


It’s Never Too Early for Cold Chain Planning for Cellular Therapies

October 01, 2016

New cellular therapies underscore the complexity of cold chain logistics with new requirements that may be unfamiliar to even experienced supply chain managers. Writing in Applied Clinical Trials, Tamie Joeckel, senior vice president of client services and consulting for Cryoport, notes that in addition to strict temperature guidelines, these cellular-based therapies have multi-step supply chains that present a new layer of complexity to scheduling, tracking and tracing because the distribution is also extremely time-sensitive. Learn how these challenges are changing both shipping containers and the sophisticated logistics systems that track them. Read more >

The Complexity of Cold Chain Logistics

September 08, 2016

Cell and gene therapy is now considered “the third pillar” of health care — along with traditional pharmaceuticals and biologic drugs. One critical challenge in the commercialization of cell and gene therapies is the complex logistics required for their handling. Any delay or temperature excursion can jeopardize the quality of these materials and, ultimately, the results of the clinical trial. In a recent article in Contract Pharma, Mark W. Sawicki, Ph.D., chief commercial officer of Cryoport, discusses how success in the clinical trial process depends upon a strategic logistics plan that includes packaging, transport, storage and handling support. Read more >

Tags: Cold Chain


Cryoport Launching Logistics Study for Bioanalytical and Clinical Trial Materials

August 30, 2016

Cryoport launched a study examining the effects of temperature and transport packaging on biomarkers and cell-therapy cancer vaccines. Currently, little research has examined shipping conditions’ effect on sample integrity. The study results will help educate clients and ensure that the most optimal shipping conditions are used when transporting materials for clinical trials. Mark W. Sawicki, Ph.D., chief commercial officer of Cryoport, explains the impact in an interview with Outsourcing Pharma. Read more >

CenterWatch Interview: Cryoport’s Chief Commercial Officer, Mark W. Sawicki, Ph.D., on a New Era of Logistics Challenges

August 22, 2016

Logistics, and particularly cold chain logistics, has taken an increasingly important role in the development of new therapeutics. With the advent of regenerative medicines and personalized therapies, many advanced cell and gene therapies are extremely sensitive to temperature. Companies that may have once approached logistics as an afterthought are formulating detailed logistics plans factoring in temperature control, time and detailed point-to-point monitoring. In an interview with CenterWatch, Mark W. Sawicki, Ph.D., chief commercial officer of Cryoport, describes the challenges and solutions of cryogenic transport in a new age of therapeutic development. Read more >

Cryoport to Convert Life Science Shipping Logistics For Contract Manufacturer

August 06, 2016

Cryoport continues to grow with the recent signing of an agreement with a leading contract biopharmaceutical supplier to convert its current fleet of liquid nitrogen (LN2) dewars to Cryoport’s comprehensive shipping solution. The client will use Cryoport Express® shippers and Cryoport’s advanced SmartPak II™ condition monitoring system for its contract manufacturing biologics and cell therapy businesses. Read more >

Supply Chain Challenges with New Therapies

July 07, 2016

Supply chains for many regenerative therapies can be very complex. Where traditional pharmaceuticals have linear supply chain models, autologous cell therapies oftentimes require circular supply chains, with little room for error. Tamie Joeckel, senior vice president, client services and consulting, discusses comprehensive strategies used to mitigate risk and manage cold chain complexities. Read more >


The Best Chance of Delivery for Life-Giving Shipments

June 21, 2016

As Asia’s pharmaceutical and biopharmaceutical industries grow, the infrastructure, supply chain management and logistics management challenges necessitate innovation. The need for proper shipping practices, including deep frozen and temperature-controlled logistics, will increase and continue to drive demand for these services. Cryoport’s innovative cold chain services and technologies meet the demands of the operational and regulatory complexities of the region. 
Read more >